Cargando…
Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study
Aim: To elucidate the role of pentraxin-3 (PTX3) in atherosclerosis, we evaluated lipid and cardiovascular risk profiles according to the plasma PTX3 levels in subjects from the general population. Methods: A sub-cohort of 2,000 subjects was randomly sampled from a Korean community-based cohort stud...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711843/ https://www.ncbi.nlm.nih.gov/pubmed/30674758 http://dx.doi.org/10.5551/jat.47167 |
_version_ | 1783446569565028352 |
---|---|
author | Lee, Ran Ahn, Hye-Ran Shin, Min-Ho Kim, Hee-Nam Lee, Young-Hoon Choi, Seong-Woo Kweon, Sun-Seog |
author_facet | Lee, Ran Ahn, Hye-Ran Shin, Min-Ho Kim, Hee-Nam Lee, Young-Hoon Choi, Seong-Woo Kweon, Sun-Seog |
author_sort | Lee, Ran |
collection | PubMed |
description | Aim: To elucidate the role of pentraxin-3 (PTX3) in atherosclerosis, we evaluated lipid and cardiovascular risk profiles according to the plasma PTX3 levels in subjects from the general population. Methods: A sub-cohort of 2,000 subjects was randomly sampled from a Korean community-based cohort study. After excluding those with a medication history for dyslipidemia, 1,747 subjects (902 men and 845 women) were included in the final analyses. Linear and logistic regressions with adjustment for appropriate variables were performed. Results: The PTX3 level was positively associated with the high-density lipoprotein cholesterol (HDL-C) level and negatively associated with the log-transformed triglyceride (TG) level, total cholesterol/HDL-C ratio, and low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio (p<0.05). Subjects with the highest PTX3 levels (≥ 1.17 ng/dl) exhibited a lower risk of metabolic syndrome (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.57–0.94), overweight/obesity (OR 0.65, 95% CI 0.50–0.83), increased TG level (OR 0.66, 95% CI 0.51–0.86), and increased HDL-C level (OR 0.67, 95% CI 0.51–0.88) compared to those with the lowest PTX3 level (<0.7 ng/dl). Conclusion: The circulating PTX3 level was inversely associated with metabolic syndrome, overweight/obesity, and parameters of dyslipidemia, suggesting a cardioprotective role of PTX3 in atherosclerosis. |
format | Online Article Text |
id | pubmed-6711843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Japan Atherosclerosis Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-67118432019-09-22 Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study Lee, Ran Ahn, Hye-Ran Shin, Min-Ho Kim, Hee-Nam Lee, Young-Hoon Choi, Seong-Woo Kweon, Sun-Seog J Atheroscler Thromb Original Article Aim: To elucidate the role of pentraxin-3 (PTX3) in atherosclerosis, we evaluated lipid and cardiovascular risk profiles according to the plasma PTX3 levels in subjects from the general population. Methods: A sub-cohort of 2,000 subjects was randomly sampled from a Korean community-based cohort study. After excluding those with a medication history for dyslipidemia, 1,747 subjects (902 men and 845 women) were included in the final analyses. Linear and logistic regressions with adjustment for appropriate variables were performed. Results: The PTX3 level was positively associated with the high-density lipoprotein cholesterol (HDL-C) level and negatively associated with the log-transformed triglyceride (TG) level, total cholesterol/HDL-C ratio, and low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio (p<0.05). Subjects with the highest PTX3 levels (≥ 1.17 ng/dl) exhibited a lower risk of metabolic syndrome (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.57–0.94), overweight/obesity (OR 0.65, 95% CI 0.50–0.83), increased TG level (OR 0.66, 95% CI 0.51–0.86), and increased HDL-C level (OR 0.67, 95% CI 0.51–0.88) compared to those with the lowest PTX3 level (<0.7 ng/dl). Conclusion: The circulating PTX3 level was inversely associated with metabolic syndrome, overweight/obesity, and parameters of dyslipidemia, suggesting a cardioprotective role of PTX3 in atherosclerosis. Japan Atherosclerosis Society 2019-08-01 /pmc/articles/PMC6711843/ /pubmed/30674758 http://dx.doi.org/10.5551/jat.47167 Text en 2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Original Article Lee, Ran Ahn, Hye-Ran Shin, Min-Ho Kim, Hee-Nam Lee, Young-Hoon Choi, Seong-Woo Kweon, Sun-Seog Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study |
title | Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study |
title_full | Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study |
title_fullStr | Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study |
title_full_unstemmed | Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study |
title_short | Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study |
title_sort | association of plasma pentraxin-3 level with lipid levels and cardiovascular risk factors in people with no history of lipid-lowering medication: the dong-gu study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711843/ https://www.ncbi.nlm.nih.gov/pubmed/30674758 http://dx.doi.org/10.5551/jat.47167 |
work_keys_str_mv | AT leeran associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy AT ahnhyeran associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy AT shinminho associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy AT kimheenam associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy AT leeyounghoon associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy AT choiseongwoo associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy AT kweonsunseog associationofplasmapentraxin3levelwithlipidlevelsandcardiovascularriskfactorsinpeoplewithnohistoryoflipidloweringmedicationthedonggustudy |